Compare Gitlab Inc (GTLB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Illumina, Inc. — how do they compare? Gitlab Inc trades at $41.23 (market cap $7.11B), while Illumina, Inc. trades at $190.86 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 4.1× Gitlab Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | ILMN | |
|---|---|---|
Market Cap | $7.11B | $29.12B |
Sector | Technology | Health |
52-Week High | $51.04 | $205.10 |
52-Week Low | $19.42 | $91.00 |
Enterprise Value | $5.85B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.98, up 0.61% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Revenue grew to $759.25M in 2025, with a high gross margin of 86.74%, but net income remains negative. Recent news highlights AI-driven product launches and Gartner leadership recognition, fueling positive sentiment.
Outlook: Growth prospects are robust due to AI integration and market position, but high valuation (P/E 521.22) and lack of profitability pose risks. Analyst consensus is mixed with a $32.92 price target, suggesting caution despite operational strengths.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
